Long-acting GnRH antagonist providing immediate testosterone suppression in prostate cancer without flare.
Reference facts
- Also known as
- Firmagon, FE-200486
- Category
- GnRH & Reproductive
- Mechanism of action
- Long-acting GnRH antagonist providing immediate testosterone suppression in prostate cancer without flare.
- Targets
- GnRH receptor (antagonist)
- Indications under research or approved
- Advanced prostate cancer
- Regulatory status (reference entry)
- FDA-approved (2008)
- Half-life
- ~53 days (depot at 240 mg)
- Sequence notes
- Decapeptide GnRH antagonist Ac-D-2Nal-D-4ClPhe-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2.
- Molecular weight (Da)
- 1632
- Originator / sponsor
- Ferring Pharmaceuticals
- First reported
- 2002
Primary References
Explore research articles about Degarelix
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.